Pricing pressures that have affected the US generics market over the last few years have stabilized and this will continue to be the case in the future, according to Teva chief Kåre Schultz. Speaking at the 2019 J.P. Morgan Healthcare Conference, he also revealed that the firm was on track with its restructuring and debt-reduction plan.

Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.

Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.